Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer.

Molecular cancer therapeutics - 1 Dec 2020

Somarelli Jason A, Roghani Roham Salman, Moghaddam Ali Sanjari, Thomas Beatrice C, Rupprecht Gabrielle, Ware Kathryn E, Altunel Erdem, Mantyh John B, Kim So Young, McCall Shannon J, Shen Xiling, Mantyh Christopher R, Hsu David S

Abstract excerpt

Colorectal cancer is the third most common cancer in the United States and responsible for over 50,000 deaths each year. Therapeutic options for advanced colorectal cancer are limited, and there remains an unmet clinical need to identify new treatments for this deadly disease. To address this need, we developed a precision medicine pipeline that integrates high-throughput chemical screens with matched...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Checkpoints
Share to Cyclin-Dependent Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Drug Screening Assays, Antitumor

Share to Drug Synergism

Share to High-Throughput Screening Assays

Share to Precision Medicine

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33158998
DOI: 10.1158/1535-7163.MCT-20-0454
PMCID: PMC7718319

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer.PMID 33158998Read ↗

Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.Semantic proximity Read ↗

In Search of Novel CDK8 Inhibitors by Virtual ScreeningSemantic proximity Read ↗

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer AgentsSemantic proximity Read ↗

Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complexSemantic proximity Read ↗

Andrographis overcomes 5-fluorouracil-associated chemoresistance through inhibition of DKK1 in colorectal cancerSemantic proximity Read ↗

Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal CancerSemantic proximity Read ↗

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An UpdateSemantic proximity Read ↗

Targeting CDK9 for Anti-Cancer TherapeuticsSemantic proximity Read ↗

Quinoline-5,8-Dione CDC25 Inhibitors: Potent Anti-Cancer Agents in Leukemia and Patient-Derived Colorectal OrganoidsSemantic proximity Read ↗

Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent CancersSemantic proximity Read ↗

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Semantic proximity Read ↗

In silico design and molecular docking study of CDK2 inhibitors with potent cytotoxic activity against HCT116 colorectal cancer cell lineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.